Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers

Journal of the National Cancer Institute

Volumn 84, Issue 11, 1992, Pages 845-855

  Thor, Ann D ^a   Moore, Dan H ^b   Edgerton, Susan M ^a   Kawasaki, Ernest S ^c   Reihsaus, Ellen ^c   Lynch, Henry T ^d   Marcus, Joseph N ^d   Schwartz, Laurent ^a   Chen, Ling Chun ^e   Mayall, Brian H ^f   Smith, Helene S ^e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d CREIGHTON UNIVERSITY   (United States)

^e CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CELL LINE; DNA SEQUENCE; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NORTHERN BLOTTING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; TISSUE DISTRIBUTION;

AGE FACTORS; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL LINE; CODON; COMPARATIVE STUDY; FEMALE; GENES, P53; HUMAN; LYMPHATIC METASTASIS; MIDDLE AGE; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ODDS RATIO; PROGNOSIS; PROTEIN P53; RECEPTORS, ESTROGEN; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR MARKERS, BIOLOGICAL;

EID: 0026724877     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/84.11.845     Document Type: Article

References (49)

1. Crawford LV, Pim DC, Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30:403–408, 1982
2. Mulligan LM, Matlashewski GJ, Scrable HJ, et al: Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci USA 87:5863–5867, 1990
3. Takahashi T, Nau MM, Chiba I, et al: p53: A frequent target for genetic abnormalities in lung cancer. Science 246:491–494, 1989
4. Baker SJ, Fearon ER, Nigro JM, et al: Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244:217–221, 1989
5. Nigro JM, Baker SJ, Preisinger AC, et al: Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705–708, 1989
6. Prosser J, Thompson AM, Cranston G, et al: Evidence that p53 behaves as a tumor suppressor gene in sporadic breast tumours. Oncogene 5:1573–1579, 1990
7. Finlay CA, Hinds PW, Levine AJ: The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083–1093, 1989
8. Hinds P, Finlay C, Levine AJ: Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 63:739–746, 1989
9. McBride OW, Merry D, Givol D: The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc Natl Acad Sci USA 83:130–134, 1986
10. Isobe M, Emanuel BS, Givol D, et al: Localization of gene for human p53 tumour antigen to band 17p13. Nature 320:84–85, 1986
11. Chen LC, Neubauer A, Kurisu W, et al: Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. Proc Natl Acad Sci USA 88:3847–3851, 1991
12. Malkin D, Li FP, Strong LC, et al: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233–1238, 1990
13. Srivastava S, Zou ZQ, Pirollo K, et al: Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348:747–749, 1990
14. Vogelstein B: Cancer. A deadly inheritance. Nature 348:681–682, 1990
15. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351:453–456, 1991
16. Davidoff AM, Humphrey PA, Iglehart JD, et al: Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 88:5006–5010, 1991
17. Banks L, Matlashewski G, Crawford L: Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 159:529–534, 1986
18. Bartek J, Iggo R, Gannon J, et al: Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5:893–899, 1990
19. Barter J, Bartkova J, Vojtesek B, et al: Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int J Cancer 46:839–844, 1990
20. Varley JV, Brammar WJ, Lane DP, et al: Loss of chromosome 17p13 sequences and mutation of p53 in human breast cancer. Oncogene 6:413–421, 1991
21. Gannon JV, Greaves R, Iggo R, et al: Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9:1595–1602, 1990
22. Levine AJ, Momand J: Tumor suppressor genes: The p53 and retinoblastoma sensitivity genes and gene product. Biochim Biophys Acta 1032:119–136, 1990
23. Cattoretti G, Rilke F, Andreola S, et al: p53 expression in breast cancer. Int J Cancer 41:178–183, 1988
24. Davidoff AM, Herndon JE, Glover NS, et al: Relationship between p53 overexpression and established prognostic factors in breast cancer. Surgery 110:259–264, 1991
25. Ostrowski JL, Sawan A, Wright C, et al: p53 expression in human breast cancer related to survival and prognostic factors: An immuno-histochemical study. J Pathol 164:75–81, 1991
26. Albano WA, Recabaren JA, Lynch HT, et al: Natural history of hereditary cancer of the breast and colon. Cancer 50:360–363, 1982
27. Lynch HT, Albano WA, Danes BS, et al: Genetic predisposition to breast cancer. Cancer 53:612–622, 1984
28. Lynch HT, Lynch JF: Breast cancer genetics in an oncology clinic: 328 consecutive patients. Cancer Genet Cytogenet 23:369–372, 1983
29. Lynch HT, Harris RE, Guirgis HA, et al: Familial association of breast/ovarian carcinoma. Cancer 41:1543–1549, 1978
30. Lloveras B, Edgerton S, Thor A: Evaluation of in vitro bromodeox-yuridine labeling of breast carcinomas with the use of a commercial kit. Am J Clin Pathol 95:41–47, 1991
31. American Joint Committee on Cancer, ed: Manual for Staging of Cancer, 2nd ed. Philadelphia: Lippincott, 1983, pp 127–133
32. Sambrook J, Fritsch EF, Maniatis T, eds: Molecular cloning: A laboratory manual, 2nd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory, 1989
33. Chomczynski P, Saacchi N: Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159, 1987
34. Feinberg AP, Vogelstein B: A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 132:6–13, 1983
35. Innis MA, Gelfand DH, Sninsky JJ, et al: PCR Protocols: A Guide to Methods and Applications. New York: Academic Press, 1990
36. Smith HS, Stampfer MR, Hancock MR, et al: Isolation, characterization and culture of human mammary epithelial cells. In Cell Separation: Methods and Selected Applications (Pretlow T, Pretlow TP, eds), vol 2. New York: Academic Press, 1983, pp 183–202
37. Thor A, Benz C, Moore D, et al: Stress response protein (srp-27) determination in primary human breast carcinomas: Clinical, histologic, and prognostic correlations. J Natl Cancer Inst 83:170–178, 1991
38. Potter M: Immunoglobulin-producing tumors and myeloma proteins of mice. Physiol Rev 52:631–719, 1972
39. Breslow NE, Day NE: Statistical Methods in Cancer Research, vol 1. The analysis of case-control studies. IARC Publ No. 32. Lyon: IARC, 1980
40. Cox DR: Regression models and life tables. J R Statist Soc, Ser B34:187–220, 1972
41. Dixon WJ, ed: BMDP Statistical Software. Berkeley: Univ Calif Press, 1983, pp 57–93
42. Segal MR: Regression trees for censored-data. Biometrics 44:35–47, 1988
43. Breiman L, Friedman JH, Olshen RA, et al: Classification and Regression Trees. Belmont, CA: Wadsworth, 1984
44. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163–170, 1966
45. Bischoff JR, Friedman PN, Marshak DR, et al: Human p53 is phos-phorylated by p60-cdc2 and cyclin B-cdc2. Proc Natl Acad Sci USA 87:4766–4770, 1990
46. Mørkve O, Laerum OD: Flow cytometric measurement of p53 protein expression and DNA content in paraffin-embedded tissue from bronchial carcinomas. Cytometry 12:438–444, 1991
47. McGuire WL, Tandon AK, Craig D, et al: How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 82:1006–1015, 1990
48. Fisher CJ, Barnes DM, Gillet CE, et al: Immunohistochemical staining of mutant p53 proteins in human mammary carcinoma. Br J Cancel 62(suppl 12):23, 1990
49. Davidoff AM, Kerns BM, Iglehart JD, et al: Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 51:2605–2610, 1991